The EGFR inhibitor is a standard therapy for non-small cell lung cancer (NSCLC) patients with EGFR mutation. Recently, MET gene amplification has been identified as one of the important resistant mechanism in patients with EGFR inhibitor treatment. The results of a phase Ib clinical trial (TATTON) were presented at the 2019 AACR Annual Meeting. The NSCLC patients who have disease progression following 1st, 2nd and 3rd EGFR inhibitors were screened with EGFR T790M negative and MET amplification. In 46 patients received osimertinib plus savolitinib, the objective response rate was 52% (24/46), and the median duration of response was 7.1 months. The all-grade adverse events (AE) was 91％ (42/46). The serious adverse events (SAE) was 37% (17/46). Two AE-related deaths were reported. These results revealed that the MET-amplified NSCLC patients received osimertinib plus savolitinib showed clinical benefits and acceptable risk-benefit profile. The further research is needed to evaluate the efficacy and the safety of the combinational therapy.
2019 AACR Annual Meeting. Abstract CT032.